Today CADTH is pleased to announce operational changes that will enhance our Common Drug Review and pan-Canadian Oncology Drug Review programs. These changes reflect our careful consideration of stakeholder feedback and input from the participating jurisdictions.
For complete details regarding the revised biosimilar review process and application fees, as well as additional program updates, please see:
- CDR Update — Issue 133
- pCODR Update 63
- New Fee Guidance for Applications to CADTH’s Pharmaceutical Review Programs
To receive future updates and news from CADTH, please subscribe to our E-Alert.